WALTHAM, Mass., Oct. 22 /PRNewswire-FirstCall/ -- Repligen Corporation
(Nasdaq: RGEN) announced today that the Company President and Chief Executive
Officer, Walter C. Herlihy, Ph.D., will speak at the Rodman & Renshaw Techvest
6th Annual Healthcare Conference on Tuesday, October 26, 2004 at 10:05 A.M. ET
at the Waldorf=Astoria Hotel, 120 East 50th St., New York, New York. A live
audio-webcast of the presentation will be available at
http://www.wallstreetwebcasting.com/webcast/rrshq4/rgen and will be archived
for 30 days following the presentation. The presentation may also be accessed
via Repligen's website at http://www.repligen.com.
About Repligen Corporation
Repligen Corporation is a biopharmaceutical company committed to being the
leader in the development of novel therapeutics for profound neuropsychiatric
disorders and autoimmune disease with particular emphasis on applications for
children. Repligen has a Specialty Pharmaceuticals business comprised of
rProtein A(TM) and SecreFlo(TM), the profits from which will be used to
partially support the development of our proprietary products. Repligen's
corporate headquarters are located at 41 Seyon Street, Building #1, Suite 100,
Waltham, MA 02453. Additional information may be requested from
http://www.repligen.com.
This press release contains forward-looking statements which are made
pursuant to the safe harbor provisions of Section 27A of the Securities Act of
1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. The forward-looking statements in this press release do not
constitute guarantees of future performance. Investors are cautioned that
statements in this press release which are not strictly historical statements,
including, without limitation, statements regarding current or future
financial performance, management's strategy, plans and objectives for future
operations, clinical trials and results, litigation strategy, product
research, intellectual property, development and manufacturing plans,
constitute forward-looking statements. Such forward-looking statements are
subject to a number of risks and uncertainties that could cause actual results
to differ materially from those anticipated, including, without limitation,
risks associated with: the success of current and future collaborative
relationships, the success of our clinical trials and our ability to develop
and commercialize products, our ability to obtain required regulatory
approvals, our compliance with all Food and Drug Administration regulations,
our ability to obtain, maintain and protect intellectual property rights for
our products, the risk of current and future litigation regarding our patent
and other intellectual property rights, the risk of litigation with
collaborative partners, our limited sales and marketing experience and
capabilities, our limited manufacturing capabilities and our dependence on
third-party manufacturers and value-added resellers, the market acceptance of
our products, our ability to compete with larger, better financed
pharmaceutical and biotechnology companies that may develop new approaches to
the treatment of our targeted diseases, our history of losses and expectation
of incurring continued losses, our ability to generate future revenues, our
ability to raise additional capital to continue our drug development programs,
and other risks detailed in Repligen's filings with the Securities and
Exchange Commission. Repligen assumes no obligation to update any forward-
looking information contained in this press release or with respect to the
announcements described herein.
CONTACT:
Walter C. Herlihy, Ph.D.
President and Chief Executive Officer
(781) 250-0111, ext. 2000
Laura Whitehouse
Vice President, Market Development
(781) 250-0111, ext. 2306
SOURCE Repligen Corporation
 back to top
Related links:
http://www.repligen.com
CONTACT:
Walter C. Herlihy, Ph.D., President and Chief
Executive Officer, +1-781-250-0111, ext. 2000, or Laura
Whitehouse, Vice President, Market Development, +1-781-250-0111,
ext. 2306 both of Repligen
|
